Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes

European Journal of Clinical Investigation

Volumn 34, Issue 3, 2004, Pages 205-209

  Eibl, N ^a   Krugluger, W ^a   Streit, G ^a   Schrattbauer, K ^a   Hopmeier, P ^a   Schernthaner, G ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

CD31; CD62P; CD63; Metabolic control; Platelet activation; Type 2 diabetes

Indexed keywords

ALPHA2 INTEGRIN; ANTIGEN; BIOLOGICAL MARKER; CD31 ANTIGEN; CD36 ANTIGEN; CD63 ANTIGEN; HEMOGLOBIN A1C; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERGLYCEMIA; MALE; METABOLIC REGULATION; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROSPECTIVE STUDIES;

EID: 1642565073     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01320.x     Document Type: Article

References (39)

1. Colwell JA, Winocour PD, Halushka PV. Do platelets have anything to do with diabetic microvascular disease? Diabetes 1983;32 (Suppl. 12):14-9.
2. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54.
3. Wang ZY, Shi JM, Han Y, Wang YC, Ruan CG. Comparative study of platelet activation markers in diabetes mellitus patients complicated by cerebrovascular disease. Blood Coagul Fibrinolysis 2001;12:531-7.
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
5. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000;50:1-16.
6. Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986;23:8-26.
7. Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993;19:122-8.
8. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128-38.
9. Tschoepe D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Roesen P et al. Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry 1990;11:652-6.
10. Rauch U, Ziegler D, Piolot R, Schwippert B, Benthake H, Schultheiss HP et al. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabet Med 1999;16:848-52.
11. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 2002;99:137-44.
12. Omoto S, Nomura S, Shouzu A, Hayakawa T, Shimizu H, Miyake Y et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 1999;81:271-7.
13. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Harm Metab Res 1997;29:631-5.
14. Martin S. Soluble adhesion molecules in type 1 diabetes mellitus. Horm Metab Res 1997;29:639-42.
15. Rattan V, Shen Y, Sultana C, Kumar D, Kalra VK. Glucose-induced transmigration of monocytes is linked to phosphorylation of PECAM-1 in cultured endothelial cells. Am J Physiol 1996;271:E711-E717.
16. Daviet L, McGregor JL. Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thromb Haemost 1997;78:65-9.
17. Silverstein RL, Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol 2000;11:483-91.
18. Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002;22:14-20.
19. Pischel KD, Bluestein HG, Woods VL Jr. Platelet glycoproteins Ia, Ic, and Ha are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types. J Clin Invest 1988;81:505-13.
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
21. Tschoepe D, Driesch E, Schwippert B, Lampeter EF. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie Diabetologia 1997;40:573-7.
22. Wagner B, Fasching P, Schneider B, Kurzemann S, Waldhäusl W, Lechner K et al. Platelet and endothelial cell function in patients with insulin-dependent diabetes mellitus with excellent, good, or poor metabolic control. Microvasc Res 1996;52:183-7.
23. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
24. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
25. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl JMed 1998;339:229-34.
26. Coppola L, Verrazzo G, La Marca C, Ziccardi P, Grassia A, Tirelli A et al. Effect of insulin on blood rheology in non-diabetic subjects and in patients with Type 2 diabetes mellitus. Diabet Med 1997;14:959-63.
27. Leoncini G, Signorello MG, Piana A, Carrubba M, Armani U. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. Thromb Res 1997;86:153-60.
28. Breddin HK, Krzywanek HJ, Althoff P, Kirchmaier CM, Rosak C, Schepping M et al. Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Results of the PARD Study. Int Angiol 1986;5:181-95.
29. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999;81:373-7.
30. Murakami T, Komiyama Y, Masuda M, Kido H, Nomura S, Fukuhara S et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Eur J Clin Invest 1996;26:996-1003.
31. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000;121:437-43.
32. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991;17:433-8.
33. Roshan B, Tofler GH, Weinrauch LA, Gleason RE, Keough JA, Lipinska I et al. Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism 2000;49:88-91.
34. Tschoepe D, Driesch E, Schwippert B, Nieuwenhuis HK, Gries FA. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes 1995;44:890-4.
35. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997;89:1939-43.
36. Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Lechti-Gallati S et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999;353:351-4.
37. Baumgartner-Parzer SM, Wagner L, Pettermann M, Gessl A, Waldhäusl W. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells. Diabetologia 1995;38:1367-70.
38. Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BF. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetes Metab 1989;15:420-5.
39. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G et al. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002;45:1034-7.